Walleye Capital
SRPT icon

Walleye Capital’s Sarepta Therapeutics SRPT Stock Holding History

Walleye Capital’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.13M Sell
52,000
-76,200
-59% -$1.47M ﹤0.01% 1963
2025
Q4 		$2.76M Buy
128,200
+66,300
+107% +$1.4M 0.01% 1599
2025
Q3 		$1.19M Sell
61,900
-49,000
-44% -$874K ﹤0.01% 1956
2025
Q2 		$1.9M Buy
110,900
+110,000
+12,222% +$4.69M 0.01% 1555
2025
Q1 		$57.4K Sell
900
-5,100
-85% -$537K ﹤0.01% 3808
2024
Q4 		$730K Sell
6,000
-10,500
-64% -$1.29M ﹤0.01% 2663
2024
Q3 		$2.06M Buy
16,500
+14,500
+725% +$2M ﹤0.01% 1923
2024
Q2 		$316K Sell
2,000
-3,700
-65% -$475K ﹤0.01% 3931
2024
Q1 		$738K Sell
5,700
-11,200
-66% -$1.37M ﹤0.01% 2865
2023
Q4 		$1.63M Buy
16,900
+11,200
+196% +$1.07M ﹤0.01% 1952
2023
Q3 		$691K Sell
5,700
-3,300
-37% -$373K ﹤0.01% 2553
2023
Q2 		$1.03M Sell
9,000
-2,400
-21% -$309K ﹤0.01% 1825
2023
Q1 		$1.57M Buy
11,400
+8,300
+268% +$1.08M 0.02% 860
2022
Q4 		$402K Sell
3,100
-2,600
-46% -$301K 0.01% 1595
2022
Q3 		$630K Buy
+5,700
New +$575K 0.01% 1313
2020
Q1 		– Sell
-7,700
Closed -$994K – 1592
2019
Q4 		$994K Buy
7,700
+6,300
+450% +$636K 0.06% 420
2019
Q3 		$105K Buy
+1,400
New +$165K 0.01% 1425

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Walleye Capital's SRPT Position: Q1 2026 in Review

Walleye Capital increased its Sarepta Therapeutics (SRPT) stake by 5.8% in Q1 2026, buying an estimated $306K and bringing the position to 288,532 shares worth $6.28M. The position accounts for 0.03% of the portfolio, ranked #656.

Walleye Capital first reported a position in SRPT in Q2 2019 and has held it in 19 quarters since. The position peaked at $10.5M in Q4 2023. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • Walleye Capital held 288,532 shares of Sarepta Therapeutics worth $6.28M as of Q1 2026.
  • Walleye Capital bought 15,800 Sarepta Therapeutics shares in Q1 2026, an estimated $306K.
  • Sarepta Therapeutics made up 0.03% of Walleye Capital's portfolio in Q1 2026, its #656 holding.
  • Walleye Capital first reported a position in Sarepta Therapeutics in Q2 2019 and has held it in 19 quarters since.
  • Walleye Capital's Sarepta Therapeutics position peaked at $10.5M in Q4 2023.
  • 339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.